Shire spins out mRNA group to RaNA, which is hatching plans to tackle cystic fibrosis in the clinic
Over the last few years, the executive crew at Shire has on a few rare occasions spotlighted their work in mRNA, touting its potential for adding to its forecast of billions in new revenue. A little more than two years ago, the research arm of the Cystic Fibrosis Foundation contributed $15 million to the venture. But now, with their big merger with Baxalta still being worked through, Shire is lateraling their mRNA team — more than a dozen staffers and two key programs — to RaNA Therapeutics in exchange for a chunk of equity.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.